Corcept Therapeutics Inc. has developed treatments mainly focusing on solving metabolic disorders and related problems, and have several experimental and on-sale drugs released. One of the principle drugs that the company has been developing is Korlym, which is an oral daily medication for patients with type II diabetes mellitus or glutose intolerance, and those who failed or might not be appropriate to be under surgery. In 2013, after being offered since 2012 in the US, the drug was further commercialized to the market outside the States and reached the global medical field, since the companys partnership with Idis Access Program was approved and launched. this is the first therapy approved by US Food and Drug Administration (FDA) for patients with endogenous Cushings syndrome. From 1998, the company has been studying the psychotic features of depression and developing oral medication for the symptoms. In recent years, two of the main trials were conducted with the drug CORLUX, which is a once-daily treatment given to patients, mainly in the United States.